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INTRODUCTION 
Myasthenia graves (MG) is an autoimmune disor-
der which presents as a result of antibodies which 
act against the acetylcholine receptors at the neu-
romuscular junction mostly immunoglobulin G 
(IgG) from T-cells in the thymus *1+. Myasthenia 
graves are usually characterized by fluctuating 
skeletal muscle weakness that often affects spe-
cific muscle groups *2+. It is uncommon in the 
western world but more common in Asia, pre-
senting mostly as extraocular muscle myasthenia 
graves (EOMG) with a growing prevalence rate 
and a stable mortality rate, elderly people with 
the disorder usually exhibit bulbar palsy signs *1, 
3+. The illness is usually associated with the acetyl-
choline receptor (AChR), which is a pentameric 
transmembrane protein with an alpha subunit of 
the alpha2, beta, delta, and epsilon complex forms 
the adult receptor but the others such as the beta, 
delta and epsilon can also induce myasthenia 
graves *4, 5+. 
MHC-II antigen and invariant chain processing HLA
-DRB, as well as polymorphism of cathepsin V (Cat 
V), is usually associated with the early onset of 
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myasthenia gravis *6+. For EOMG patients, the 
RNA expression of the epsilon subunit is about 
50% of myasthenia graves because the automatic 
sensitivity in myasthenia graves may occur in the 
thymus *4+. 
The antibodies are usually intrathymic therefore 
people who undergo thymomectomy exhibit im-
proved clinical symptoms. Patients with myasthe-
nia graves exhibit symptoms like thymus hyper-
plasia and thymoma (which is a paraneoplastic 
disease associated with myasthenia graves).  The 
etiology of MG is hypothesized as the possibility of 
an intrathymic protein becomes cleaved by 
granzyme B (GrB) which is a protease present in 
cytolytic T-cells. Nk-cells also produces a neoanti-
gen which is then recognized as foreign antigens. 
This mechanism of action is also common in most 
autoimmune diseases *7+.  Patients without 
known antibodies are zero negative for myasthe-
nia graves while those with antibodies like the anti
-AChR are positive myasthenia graves patients, 
they usually present with thymic hyperplasia 
which 60% are seropositive. Inflammatory cyto-
kines like IL-2, IFN-gamma, IL-1, and IL-6 have 
been linked with myasthenia graves *7+. 
Classification of myasthenia gravis and its inter-
play between thymoma and thymomectomy: 
MG is classified into various subgroups according 
to; the age of onset; presence or absence of ab-
normal thymus findings; muscle autoantibodies 
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involved; and the skeletal muscles affected, such 
as ocular MG meaning only extraocular muscles 
are affected or generalized MG which implies 
muscle weakness in different body parts*8+.   
The cutoff age used to differentiate between ear-
ly, and late-onset usually varies across studies but 
is generally between ages 40-60. This review will 
consider the age groups of early onset (<50 years) 
and late onset (>50 years) *9+.  
Early onset MG is more commonly associated with 
females, patients usually have thymic hyperplasia 
and thyroid dysfunction. Late-onset MG is more 
commonly associated with males, patients usually 
have normal thymic histology and are associated 
with the severe form of the disease and may occur 
concurrently with thymoma *1, 10+. Aside from 
these differences, titin can also be used to differ-
entiate between early onset and late onset *11+. 
They are an indicator of thymoma in early-onset 
MG while those without thymoma are usually late 
onset MG *11+. 
Some other muscles proteins like muscle-specific 
tyrosine kinase (MUSK) are usually attacked by 
antibodies in some cases of MG which present 
with severe symptoms that are mainly respiratory 
related to ocular muscles spared *10+. It usually 
has an earlier onset and is more common in fe-
males with a normal thymus histology *10+. There 
also some cases of MG in which no antibodies are 
discovered in the patient, and this is referred to as 
Seronegative MG *10+. 
Congenital myasthenia which occurs when anti-
bodies to AChR are transferred from mother to a 
child usually do not last long and does not recur 
later in life *12, 13+. Thymectomy and immuno-
suppressive treatment usually do not affect this 
condition because it is not an immunologic dis-
ease *13+.   
Thymoma-associated MG can occur in either male 
or female usually within 40-60 years with peak age 
onset at 50 *10+. It is usually associated with high 
level of AChR receptors, and antibodies to titin 
and ryanodine receptors (striated muscle pro-
teins) *10, 14+. Thymoma results from the exces-
sive growth of epithelial and regional thymic cells 
which can differentiate immature T-cells into ma-
ture T-cells and have them transported into the 
periphery which is known to cause MG *14+. The T
-cells produce epitopes causing cross-reactions 
with the striated muscle proteins and their recep-
tors (AChR, titin, and ryanodine receptors) *15+.  
MG Patients with thymoma have generalized 
weakness of the bulbar, neck, and respiratory 
muscles. It is a more severe disease which indi-
cates its worse prognosis compared to non-
thymoma associated MG and involves a higher 
level of immunosuppressive treatment *8+. Pa-
tients with thymoma are usually recommended 
for thymomectomy, which is the surgical resection 
of the thymic tissue, but studies reveal it usually 
does not affect the prevalence of MG in patients 
*8+. It was also noted that patients diagnosed at 
the age of 55 or older with thymoma-associated 
MG had a poorer prognosis when the period be-
tween the time of diagnosis and thymectomy was 
less than a year *13+. 
Myasthenia gravis and extrathymic manifesta-
tions 
MG has also been reportedly associated with ex-
trathymic manifestations. The consumption of 
immunosuppressant by patients also increase the 
chances for malignant tumors in other location of 
the body to manifest. Although, the risk and char-
acteristics of the tumors have not been well un-
derstood *16+. Myasthenia Gravis is an autoim-
mune disorder affecting AChR on skeletal muscles 
amongst other places. Cardiac muscles are also 
included as it has a parasympathetic innervation 
and thus presents as arrhythmias and heart fail-
ure. Another study investigating reports from 
2003-2013 showed that 97% of patients with MG 
had antibodies against cardiac muscles. Other 
complications reported in the study included anti-
cholinesterase induced AV block with abnormal 
ECG readings, cardiomyopathy, and giant cell my-
ocarditis (GCM) *17+. GCM was also recorded in a 
72-year-old patient medicating on azathioprine 
with no relationship amongst the area of inflam-
mation and IgG deposition. Cases of GCM after 
thymoma resection was also reported with the 
presence of CD3 lymphocytes, CD68 histiocytes 
and giant cells on histopathology. Autopsy proven 
myocarditis occurred in a case of stage IVa thy-
moma with positive AChR antibody titers but with-
out clinical MG following chemotherapy. Two cas-
es of invasive thymoma developing GCM and myo-
sitis were also reported *18+.   
Asymptomatic GCM in patients with MG with 
strongly positive striational antibodies were fatal.  
The etiology behind GCM remains unclear, and its 
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relationship with MG is not exclusive. GCM has 
been reported in other autoimmune disorders 
including Crohn's disease, rheumatoid arthritis, 
and systemic lupus erythematosus *17+. Risk fac-
tors for GCM include increased age and thymoma. 
In some cases, pericarditis has been linked to 
GCM.   
Treatment modalities: The treatment for myas-
thenia gravis could either be medical or surgical 
(thymectomy). 
As is well-known acetylcholine is the major neuro-
transmitter implicated in MG, so it is not 
farfetched that the first line of treatment for the 
disease is anticholinesterase drugs *10+. Anticho-
linesterase works by preventing the breakdown of 
acetylcholine by cholinesterase thus increasing 
the amount of acetylcholine in the synaptic cleft 
*18+. It causes a temporary relief from symptoms 
which reappears when the effect of the drug 
wears off *10+. Another form of treatment is im-
munomodulatory (immunosuppressive) drugs 
which modify the functioning of the immune sys-
tem either by suppressing the number of activated 
lymphocytes. Examples of such drugs are azathio-
prine, mycophenolate, mofetil, cyclosporine, and 
tacrolimus *10+. Steroids such as prednisolone are 
also used for MG, they are fast acting but could 
have side effects such as temporary weakness *10, 
14+.  Cyclophosphamide and rituximab are used 
for refractory cases of MG *10+. Steroids and im-
munomodulatory drugs are usually used for long-
term treatment *14+. 
Myasthenia gravis and thymectomy : An indica-
tion of Thymectomy is one of the most debated 
topics in the treatment of MG for many years, and 
no concrete consensus is reached for this indica-
tion so far. Several factors like patient’s age, sex, 
the presence of Thymoma and severity of MG, the 
presence of AChR antibodies or MuSK antibody, 
and seronegative myasthenia formation are usual-
ly considered with great caution before any resec-
tion *19+. Studies have shown that most patients 
with MG and AChR autoantibodies have thymus 
anomalies, with thymus hyperplasia seen in 60% - 
70% of cases and thymoma in 10% - 15% of cases. 
It is suggested that the removal of the thymus can 
reduce symptoms and occasionally cure patients 
possibly by rebalancing the immune system and 
benefitting patients with or without thymoma 
*18+. This is because the thymus is the primary 
organ that produces the antibodies that affect the 
AChR *18+. Cultured human thymic lymphocytes 
have been observed to produce AChR antibodies 
in vitro. Therefore, it is safe to say that the remov-
al of the MG thymus will reduce the effect and 
autoreactivity of immune cell response that caus-
es severe damage, impairment, and blockage of 
transmission to the AChR that ultimately lead to 
MG *18+. Thymectomy is considered a mainstay 
therapy for MG; leading to clinical improvement in 
70 – 80% and clinical remission is seen in about 33
-38 % of cases *8+.  
CONCLUSION 
Myasthenia gravis is an autoimmune disease with 
various etiologies. As a result, several factors are 
considered in approaching treatment with most 
patients opting out for medication rather than 
surgery. However, the beneficial role of thy-
momectomy is unprecedented and should be en-
couraged in either early or late onset surgery. An-
other advantage could also be that thymomecto-
my will prevent prolong usage of immunosuppres-
sants which could lead to further complications 
such as paraneoplastic presentations.  
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